Financial Performance - The company reported revenue of HKD 30,704,000 for the six months ended June 30, 2025, compared to HKD 30,704,000 for the same period in 2024, indicating no growth year-over-year[4] - Gross profit for the period was HKD 10,790,000, with a gross margin of approximately 35.1%[4] - The company incurred a loss attributable to owners of HKD 6,093,000, compared to a loss of HKD 4,793,000 in the previous year, reflecting a deterioration in performance[4] - The company reported a revenue growth of 16.6% to HKD 35.8 million for the six months ended June 30, 2025, compared to HKD 30.7 million in 2024[28] - The gross profit for the same period was HKD 11.5 million, with a gross margin of 32.1%, down from 35.1% in 2024[28] - The company achieved a net profit of HKD 3.4 million for the six months ended June 30, 2025, recovering from a loss of HKD 6.1 million in 2024[29] - The company’s basic and diluted loss per share for the period was HKD 1.0 cents, compared to a loss of HKD 1.9 cents per share in the previous year[4] Assets and Liabilities - The total assets as of June 30, 2025, were HKD 44,346,000, while total liabilities were HKD 38,537,000, resulting in a net asset value of HKD 2,456,000[5] - The company’s total liabilities increased from HKD 52,211,000 as of December 31, 2024, to HKD 38,537,000 as of June 30, 2025, indicating a reduction in overall debt[10] - As of June 30, 2025, the group's net current assets increased by HKD 7.3 million to HKD 5.5 million, including cash and bank balances of HKD 9.9 million (December 31, 2024: HKD 8.8 million)[31] - The group's current ratio improved to 1.15 as of June 30, 2025 (December 31, 2024: 1.05)[31] - The total borrowings remained relatively stable at HKD 31.3 million as of June 30, 2025 (December 31, 2024: HKD 33.1 million)[31] Income and Expenses - The company reported other income of HKD 8,471,000, which included rental income of HKD 309,000 and other income of HKD 8,162,000[12] - The financing costs for the period amounted to HKD 486,000, which included interest expenses on bank loans and lease liabilities[13] - Administrative expenses decreased by 45.2% to HKD 4.6 million, down from HKD 8.4 million in 2024, due to effective cost control measures[29] - The fair value loss on listed equity investments was HKD 2.8 million for the six months ended June 30, 2025, compared to HKD 15.1 million in 2024[30] Business Operations - The company’s medical and health business generated external sales of HKD 35,771,000, with a segment profit of HKD 8,662,000[9] - The company has one reportable segment, which is the distribution of medical and health equipment and products, with no new segments introduced during the reporting period[8] - The company has not acquired any property, plant, and equipment during the six months ended June 30, 2025[18] - The Hong Kong medical equipment market is expected to grow at a rate of 8.3% in 2025 and continue at a compound annual growth rate of 7.6% from 2025 to 2030[27] - The company plans to expand its product sources and portfolio while maintaining its market position and providing high-quality services[27] - The group remains optimistic about the Hong Kong medical device market and aims for organic growth through improved business models and increased market penetration[33] Employee and Management - As of June 30, 2025, the group had 20 employees, with employee costs amounting to HKD 1.9 million for the six months ended June 30, 2025 (2024: HKD 3.2 million)[41] - The board of directors is actively seeking suitable candidates to fill the vacant positions of chairman and CEO[58] Corporate Governance - The company is committed to maintaining high standards of corporate governance and has complied with the corporate governance code during the reporting period[58] - The audit committee, composed of three independent non-executive directors, has reviewed the interim financial statements and found them compliant with applicable accounting standards[59] - The company has adopted the standards set out in Appendix C3 of the listing rules to regulate securities trading by directors[57] Stock Options - The stock option plan is effective for 10 years starting from June 30, 2025, subject to early termination provisions[53] - The total number of stock options available for grant as of June 30, 2025, is 32,603,682, representing 10% of the issued shares as of the report date[55] - The board of directors must not grant stock options that would result in any participant holding more than 1% of the total issued shares within any 12-month period without shareholder approval[54] - There are no other share-linked agreements in place during the reporting period or as of June 30, 2025, apart from the stock option plan[56] Financial Management - The group maintained a cautious financial management policy, closely monitoring liquidity ratios to meet capital requirements[40] - The group has not completed any equity fundraising activities during the six months ended June 30, 2025[34] - There were no significant investments or acquisitions during the six months ended June 30, 2025[35] - The group has no significant assets pledged as collateral as of June 30, 2025[37]
京玖康疗(00648) - 2025 - 中期业绩